{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:23:44Z","timestamp":1789579424926,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG03949"],"award-info":[{"award-number":["P01 AG03949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017979","name":"Carolyne E Czap and Eugene A Czap Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017979","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leonard and Sylvia Marx Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Subjective cognitive concerns (SCC) have emerged as important early indicators of Alzheimer\u2019s disease (AD) risk. Traditional measures of SCC rely on recall-based assessments, which may be limited in capturing real-time fluctuations in cognitive concerns. Ecological Momentary Assessment (EMA) offers a promising alternative by providing real-time data. This study aimed to link SCC assessed via EMA and traditional measures with blood-based AD biomarkers in a diverse, dementia-free, community-based sample based in the Bronx, NY.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Einstein Aging Study (EAS) participants underwent in-person, recall-based assessments of SCC during an in-clinic visit. Additionally, EMA SCC assessments were collected once per day over two weeks. Linear regressions were conducted to examine the relationships between SCC variables and plasma biomarkers adjusted for demographics and mild cognitive impairment (MCI) status.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In <jats:italic>N<\/jats:italic>\u2009=\u2009254 participants, EMA-reported SCCs demonstrated significant associations with AD biomarkers, particularly p-tau181 (\u03b2\u2009=\u20090.21, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Further, significant associations remain across both cognitive (cognitively unimpaired vs. MCI) and racial groups. In contrast, traditional SCC measures exhibited limited associations with these biomarkers. The findings highlight the added value of EMA in capturing SCCs that could indicate early ADRD risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>EMA provides a more dynamic and potentially sensitive method for detecting early AD risk compared to traditional SCC assessments. These real-time measures could enhance early detection and clinical intervention, particularly in diverse and under-resourced populations. This study underscores the potential of EMA for broad applicability and inclusivity in monitoring AD progression and facilitating early therapeutic interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01720-y","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T06:55:23Z","timestamp":1744700123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Enhanced associations between subjective cognitive concerns and blood-based AD biomarkers using a novel EMA approach"],"prefix":"10.1186","volume":"17","author":[{"given":"\u00c1ngel","family":"Garc\u00eda de la Garza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Mogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Derby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"1720_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack","year":"2008","unstructured":"Jack CR, et al. The Alzheimer\u2019s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685\u201391.","journal-title":"J Magn Reson Imaging"},{"key":"1720_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2014;10:844\u201352.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jalz.2007.01.011","volume":"3","author":"M van Oijen","year":"2007","unstructured":"van Oijen M, de Jong FJ, Hofman A, Koudstaal PJ, Breteler M. M. B. Subjective memory complaints, education, and risk of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2007;3:92\u20137.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1041610207006412","volume":"20","author":"B Reisberg","year":"2008","unstructured":"Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer\u2019s disease. Int Psychogeriatr. 2008;20:1\u201316.","journal-title":"Int Psychogeriatr"},{"key":"1720_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271\u20138.","journal-title":"Lancet Neurol"},{"key":"1720_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-023-01341-3","volume":"15","author":"L Perna","year":"2023","unstructured":"Perna L, et al. Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study. Alz Res Therapy. 2023;15:198.","journal-title":"Alz Res Therapy"},{"key":"1720_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2014.06.004","volume":"11","author":"C Laske","year":"2015","unstructured":"Laske C, et al. Innovative diagnostic tools for early detection of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2015;11:561\u201378.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1017\/S0959259812000172","volume":"23","author":"RE Mark","year":"2013","unstructured":"Mark RE, Sitskoorn MM. Are subjective cognitive complaints relevant in preclinical Alzheimer\u2019s disease? A review and guidelines for healthcare professionals. Reviews Clin Gerontol. 2013;23:61\u201374.","journal-title":"Reviews Clin Gerontol"},{"key":"1720_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jalz.2016.09.012","volume":"13","author":"JL Molinuevo","year":"2017","unstructured":"Molinuevo JL, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimer\u2019s Dement. 2017;13:296\u2013311.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1037\/neu0000888","volume":"37","author":"LA Rabin","year":"2023","unstructured":"Rabin LA, et al. Linking self-perceived cognitive functioning questionnaires using item response theory: the subjective cognitive decline initiative. Neuropsychology. 2023;37:463\u201399.","journal-title":"Neuropsychology"},{"issue":"Suppl 1","key":"1720_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-150154","volume":"48","author":"LA Rabin","year":"2015","unstructured":"Rabin LA, et al. Subjective cognitive decline in older adults: an overview of Self-Report measures used across 19 international research studies. J Alzheimers Dis. 2015;48(Suppl 1):63\u201386.","journal-title":"J Alzheimers Dis"},{"key":"1720_CR12","doi-asserted-by":"crossref","unstructured":"Bubbico G et al. Subjective cognitive decline and nighttime sleep alterations, a longitudinal analysis. Front Aging Neurosci. 2019;11.","DOI":"10.3389\/fnagi.2019.00142"},{"key":"1720_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jalz.2018.10.003","volume":"15","author":"RER Slot","year":"2019","unstructured":"Slot RER, et al. Subjective cognitive decline and rates of incident Alzheimer\u2019s disease and non\u2013Alzheimer\u2019s disease dementia. Alzheimer\u2019s Dement. 2019;15:465\u201376.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR14","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.nicl.2021.102923","volume":"33","author":"C Morrison","year":"2022","unstructured":"Morrison C, Dadar M, Shafiee N, Villeneuve S. Louis Collins, D. Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. NeuroImage: Clin. 2022;33:102923.","journal-title":"NeuroImage: Clin"},{"key":"1720_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/13607863.2020.1861214","volume":"26","author":"MJ Brown","year":"2022","unstructured":"Brown MJ, Hill NL, Haider MR. Age and gender disparities in depression and subjective cognitive decline-related outcomes. Aging Ment Health. 2022;26:48\u201355.","journal-title":"Aging Ment Health"},{"key":"1720_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3928\/00989134-20220110-01","volume":"48","author":"MJ Brown","year":"2022","unstructured":"Brown MJ, et al. Gender and Racial\/Ethnic disparities in social determinants of health and subjective cognitive decline: the mediating role of depression. J Gerontol Nurs. 2022;48:13\u201322.","journal-title":"J Gerontol Nurs"},{"key":"1720_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/13825585.2023.2249181","volume":"30","author":"FC Goldstein","year":"2023","unstructured":"Goldstein FC, et al. Subjective cognitive complaints in white and African American older adults: associations with demographic, mood, cognitive, and neuroimaging features. Aging Neuropsychol Cognition. 2023;30:957\u201370.","journal-title":"Aging Neuropsychol Cognition"},{"key":"1720_CR18","doi-asserted-by":"crossref","unstructured":"Schmitter-Edgecombe M, Sumida C, Cook DJ. Bridging the gap between performance-based assessment and self-reported everyday functioning: An ecological momentary assessment approach. Clin Neuropsychol. 2020 May;34(4):678-699. doi: 10.1080\/13854046.2020.1733097. Epub 2020 Mar 19. PMID: 32189568; PMCID: PMC7225027. https:\/\/pubmed.ncbi.nlm.nih.gov\/32189568\/","DOI":"10.1080\/13854046.2020.1733097"},{"key":"1720_CR19","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.2196\/14328","volume":"8","author":"E Weizenbaum","year":"2020","unstructured":"Weizenbaum E, Torous J, Fulford D. Cognition in context: Understanding the everyday predictors of cognitive performance in a new era of measurement. JMIR mHealth uHealth. 2020;8:e14328.","journal-title":"JMIR mHealth uHealth"},{"key":"1720_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/arclin\/acae016","volume":"39","author":"C Harris","year":"2024","unstructured":"Harris C, et al. Digital neuropsychology beyond computerized cognitive assessment: applications of novel digital technologies. Arch Clin Neuropsychol. 2024;39:290\u2013304.","journal-title":"Arch Clin Neuropsychol"},{"key":"1720_CR21","doi-asserted-by":"publisher","first-page":"e0226409","DOI":"10.1371\/journal.pone.0226409","volume":"14","author":"SJW Verhagen","year":"2019","unstructured":"Verhagen SJW, et al. Measuring within-day cognitive performance using the experience sampling method: A pilot study in a healthy population. PLoS ONE. 2019;14:e0226409.","journal-title":"PLoS ONE"},{"key":"1720_CR22","doi-asserted-by":"publisher","first-page":"e19852","DOI":"10.2196\/19852","volume":"3","author":"SL Bartels","year":"2020","unstructured":"Bartels SL, van Knippenberg RJM, Malinowsky C, Verhey FRJ, Vugt ME. de. Smartphone-Based experience sampling in people with mild cognitive impairment: feasibility and usability study. JMIR Aging. 2020;3:e19852.","journal-title":"JMIR Aging"},{"key":"1720_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1177\/10731911221077962","volume":"30","author":"J Mogle","year":"2023","unstructured":"Mogle J, et al. Measuring memory lapses and their impact on daily life: results from two daily diary studies. Assessment. 2023;30:1454\u201366.","journal-title":"Assessment"},{"key":"1720_CR24","doi-asserted-by":"publisher","first-page":"101446","DOI":"10.1016\/j.arr.2021.101446","volume":"71","author":"Y-R Chen","year":"2021","unstructured":"Chen Y-R, et al. Diagnostic accuracy of blood biomarkers for Alzheimer\u2019s disease and amnestic mild cognitive impairment: A meta-analysis. Ageing Res Rev. 2021;71:101446.","journal-title":"Ageing Res Rev"},{"key":"1720_CR25","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, et al. Performance of plasma phosphorylated Tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405.","journal-title":"Nat Med"},{"key":"1720_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, et al. Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80:360\u20139.","journal-title":"JAMA Neurol"},{"key":"1720_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, et al. Blood phospho-tau in alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400\u201318.","journal-title":"Nat Rev Neurol"},{"key":"1720_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","volume":"11","author":"V Chouraki","year":"2015","unstructured":"Chouraki V, et al. Plasma amyloid-\u03b2 and risk of Alzheimer\u2019s disease in the Framingham heart study. Alzheimers Dement. 2015;11:249\u2013e2571.","journal-title":"Alzheimers Dement"},{"key":"1720_CR29","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/ijms20174149","volume":"20","author":"VV Giau","year":"2019","unstructured":"Giau VV, Bagyinszky E, An SSA. Potential fluid biomarkers for the diagnosis of mild cognitive impairment. Int J Mol Sci. 2019;20:4149.","journal-title":"Int J Mol Sci"},{"key":"1720_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neubiorev.2021.07.007","volume":"128","author":"Y Qu","year":"2021","unstructured":"Qu Y, et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and meta-analysis. Neurosci Biobehavioral Reviews. 2021;128:479\u201386.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"1720_CR31","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"1720_CR32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimer\u2019s Dement. 2021;17:1353\u201364.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR33","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, et al. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14:e14408.","journal-title":"EMBO Mol Med"},{"key":"1720_CR34","doi-asserted-by":"publisher","first-page":"e0138866","DOI":"10.1371\/journal.pone.0138866","volume":"11","author":"IO Korolev","year":"2016","unstructured":"Korolev IO, Symonds LL, Bozoki AC, Initiative A. D. N. Predicting progression from mild cognitive impairment to Alzheimer\u2019s dementia using clinical, MRI, and plasma biomarkers via probabilistic pattern classification. PLoS ONE. 2016;11:e0138866.","journal-title":"PLoS ONE"},{"key":"1720_CR35","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18:2669\u201386.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst). 2016;3:63\u201372.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1720_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","volume":"19","author":"SE O\u2019Bryant","year":"2023","unstructured":"O\u2019Bryant SE, Petersen M, Hall J, Johnson LA. Team, for the H.-H. S. Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: important considerations for clinical trials and practice. Alzheimer\u2019s Dement. 2023;19:36\u201343.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR38","first-page":"e12475","volume":"15","author":"CE Munro","year":"2023","unstructured":"Munro CE, et al. Recent contributions to the field of subjective cognitive decline in aging: A literature review. Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit. 2023;15:e12475.","journal-title":"Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit"},{"key":"1720_CR39","first-page":"505","volume":"136","author":"X Yu","year":"2023","unstructured":"Yu X, et al. Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer\u2019s disease. Chin Med J. 2023;136:505.","journal-title":"Chin Med J"},{"key":"1720_CR40","doi-asserted-by":"publisher","first-page":"e1866","DOI":"10.1212\/WNL.0000000000201072","volume":"99","author":"A Rostamzadeh","year":"2022","unstructured":"Rostamzadeh A, Bohr L, Wagner M, Baethge C, Jessen F. Progression of subjective cognitive decline to MCI or dementia in relation to biomarkers for alzheimer disease. Neurology. 2022;99:e1866\u201374.","journal-title":"Neurology"},{"key":"1720_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13195-020-00738-8","volume":"12","author":"J Stockmann","year":"2020","unstructured":"Stockmann J, et al. Amyloid-\u03b2 misfolding as a plasma biomarker indicates risk for future clinical Alzheimer\u2019s disease in individuals with subjective cognitive decline. Alz Res Therapy. 2020;12:169.","journal-title":"Alz Res Therapy"},{"key":"1720_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2967\/jnumed.122.264279","volume":"64","author":"EM Coomans","year":"2023","unstructured":"Coomans EM, et al. A Head-to-Head comparison between plasma pTau181 and Tau PET along the Alzheimer\u2019s disease continuum. J Nucl Med. 2023;64:437\u201343.","journal-title":"J Nucl Med"},{"key":"1720_CR43","doi-asserted-by":"publisher","first-page":"120805","DOI":"10.1016\/j.jns.2023.120805","volume":"453","author":"G Giacomucci","year":"2023","unstructured":"Giacomucci G, et al. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s disease pathology in subjective cognitive decline and mild cognitive impairment. J Neurol Sci. 2023;453:120805.","journal-title":"J Neurol Sci"},{"key":"1720_CR44","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, et al. Plasma brain-derived Tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat Commun. 2024;15:2908.","journal-title":"Nat Commun"},{"key":"1720_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, et al. Plasma biomarker strategy for selecting patients with alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 2024;81:69\u201378.","journal-title":"JAMA Neurol"},{"key":"1720_CR46","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, et al. Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555.","journal-title":"Nat Commun"},{"key":"1720_CR47","doi-asserted-by":"publisher","unstructured":"Bolton CJ et al. Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognition. 2023.11.03.23298051 Preprint at https:\/\/doi.org\/10.1101\/2023.11.03.23298051 (2023).","DOI":"10.1101\/2023.11.03.23298051"},{"key":"1720_CR48","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/alz.12511","volume":"18","author":"CE Gleason","year":"2022","unstructured":"Gleason CE, et al. Alzheimer\u2019s disease biomarkers in black and non-Hispanic white cohorts: A contextualized review of the evidence. Alzheimer\u2019s Dement. 2022;18:1545\u201364.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR49","doi-asserted-by":"crossref","unstructured":"Wooten KG. Racial and ethnic differences in subjective cognitive Decline \u2014 United States, 2015\u20132020. MMWR Morb Mortal Wkly Rep 2023;72.","DOI":"10.15585\/mmwr.mm7210a1"},{"key":"1720_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/WAD.0b013e31823dbcfc","volume":"26","author":"MJ Katz","year":"2012","unstructured":"Katz MJ, et al. Age and sex specific prevalence and incidence of mild cognitive impairment, dementia and Alzheimer\u2019s dementia in Blacks and Whites: A report from the Einstein aging study. Alzheimer Dis Assoc Disord. 2012;26:335\u201343.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1720_CR51","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1046\/j.1532-5415.2003.51455.x","volume":"51","author":"R Lipton","year":"2003","unstructured":"Lipton R, et al. Screening for dementia by telephone using the memory impairment screen. J Am Geriatr Soc. 2003;51:1382\u201390.","journal-title":"J Am Geriatr Soc"},{"key":"1720_CR52","unstructured":"Nester C, Saykin MJKM, Lipton A, R., Rabin L. The Cognitive Change Index Supplement (CCI-40): Broadening the assessment of subjective cognitive concerns in demographically diverse community dwelling older adults. in International Neuropsychological Society Annual Meeting, Virtual (2024)."},{"key":"1720_CR53","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3233\/JAD-150729","volume":"51","author":"C Rattanabannakit","year":"2016","unstructured":"Rattanabannakit C, et al. The cognitive change index as a measure of self and informant perception of cognitive decline: relation to neuropsychological tests. J Alzheimer\u2019s Disease. 2016;51:1145\u201355.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1720_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/geronb\/gbx012","volume":"74","author":"J Mogle","year":"2019","unstructured":"Mogle J, Mu\u00f1oz E, Hill NL, Smyth JM, Sliwinski MJ. Daily memory lapses in adults: characterization and influence on affect. Journals Gerontology: Ser B. 2019;74:59\u201368.","journal-title":"Journals Gerontology: Ser B"},{"key":"1720_CR55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","volume":"17","author":"AJ Jak","year":"2009","unstructured":"Jak AJ, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatric Psychiatry. 2009;17:368\u201375.","journal-title":"Am J Geriatric Psychiatry"},{"key":"1720_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","volume":"42","author":"MW Bondi","year":"2014","unstructured":"Bondi MW, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimer\u2019s Disease. 2014;42:275\u201389.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1720_CR57","doi-asserted-by":"publisher","first-page":"e12144","DOI":"10.1002\/dad2.12144","volume":"13","author":"MJ Katz","year":"2021","unstructured":"Katz MJ, et al. T-MoCA: A valid phone screen for cognitive impairment in diverse community samples. Alzheimers Dement (Amst). 2021;13:e12144.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1720_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/01688638408401233","author":"H Buschke","year":"1984","unstructured":"Buschke H. Cued recall in amnesia. J Clin Exp Neuropsychol. 1984. https:\/\/doi.org\/10.1080\/01688638408401233","journal-title":"J Clin Exp Neuropsychol"},{"key":"1720_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuropsychologia.2010.10.026","volume":"49","author":"KL Possin","year":"2011","unstructured":"Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer\u2019s disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011;49:43\u20138.","journal-title":"Neuropsychologia"},{"key":"1720_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"RM Reitan","year":"1958","unstructured":"Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271\u20136.","journal-title":"Percept Mot Skills"},{"key":"1720_CR61","unstructured":"Benton AL, deS K, Sivan AB. Multilingual aphasia examination. AJA associates; 1994."},{"key":"1720_CR62","unstructured":"Wechsler D, De Lemos MM. & others. Wechsler Adult Intelligence Scale-Revised. vol. 1Psychological Corporation New York, (1981)."},{"key":"1720_CR63","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1017\/S1355617719000560","volume":"25","author":"A Stasenko","year":"2019","unstructured":"Stasenko A, Jacobs DM, Salmon DP, Gollan TH. The multilingual naming test (MINT) as a measure of picture naming ability in Alzheimer\u2019s disease. J Int Neuropsychol Soc. 2019;25:821\u201333.","journal-title":"J Int Neuropsychol Soc"},{"key":"1720_CR64","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archneur.1992.00530360051017","volume":"49","author":"AU Monsch","year":"1992","unstructured":"Monsch AU, et al. Comparisons of verbal fluency tasks in the detection of dementia of the alzheimer type. Arch Neurol. 1992;49:1253\u20138.","journal-title":"Arch Neurol"},{"key":"1720_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1037\/neu0000933","volume":"38","author":"EL Weizenbaum","year":"2024","unstructured":"Weizenbaum EL, et al. Capturing learning curves with the multiday Boston remote assessment of neurocognitive health (BRANCH): feasibility, reliability, and validity. Neuropsychology. 2024;38:198\u2013210.","journal-title":"Neuropsychology"},{"key":"1720_CR66","doi-asserted-by":"publisher","first-page":"e12217","DOI":"10.1002\/dad2.12217","volume":"13","author":"F \u00d6hman","year":"2021","unstructured":"\u00d6hman F, Hassenstab J, Berron D, Sch\u00f6ll M, Papp K. V. Current advances in digital cognitive assessment for preclinical Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2021;13:e12217.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1720_CR67","first-page":"e12500","volume":"15","author":"LI Thompson","year":"2023","unstructured":"Thompson LI, et al. Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit. 2023;15:e12500.","journal-title":"Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit"},{"key":"1720_CR68","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/jnnp.2008.154146","volume":"80","author":"C Reitz","year":"2009","unstructured":"Reitz C, Honig L, Vonsattel JP, Tang M-X, Mayeux R. Memory performance is related to amyloid and Tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry. 2009;80:715\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1720_CR69","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1038\/s41467-019-12921-z","volume":"10","author":"TM Harrison","year":"2019","unstructured":"Harrison TM, et al. Tau deposition is associated with functional isolation of the hippocampus in aging. Nat Commun. 2019;10:4900.","journal-title":"Nat Commun"},{"key":"1720_CR70","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","volume":"144","author":"D Berron","year":"2021","unstructured":"Berron D, et al. Early stages of Tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144:2771\u201383.","journal-title":"Brain"},{"key":"1720_CR71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1533317512467679","volume":"28","author":"AM Gilligan","year":"2013","unstructured":"Gilligan AM, Malone DC, Warholak TL, Armstrong EP. Health disparities in cost of care in patients with Alzheimer\u2019s disease: an analysis across 4 state medicaid populations. Am J Alzheimers Dis Other Demen. 2013;28:84\u201392.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1720_CR72","first-page":"872","volume":"28","author":"J Balls-Berry","year":"2022","unstructured":"Balls-Berry J, Joy E, Babulal GM. Health disparities in dementia. Continuum (Minneap Minn). 2022;28:872\u201384.","journal-title":"Continuum (Minneap Minn)"},{"key":"1720_CR73","first-page":"891","volume":"5","author":"KZ Gianattasio","year":"2019","unstructured":"Gianattasio KZ, Prather C, Glymour MM, Ciarleglio A, Power MC. Racial disparities and Temporal trends in dementia misdiagnosis risk in the united States. Alzheimer\u2019s Dementia: Translational Res Clin Interventions. 2019;5:891\u20138.","journal-title":"Alzheimer\u2019s Dementia: Translational Res Clin Interventions"},{"key":"1720_CR74","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s12889-020-08820-4","volume":"20","author":"C Giebel","year":"2020","unstructured":"Giebel C, et al. Do people living in disadvantaged circumstances receive different mental health treatments than those from less disadvantaged backgrounds? BMC Public Health. 2020;20:651.","journal-title":"BMC Public Health"},{"key":"1720_CR75","unstructured":"Smith AS, Trevelyan E. The Older Population in Rural America: 2012\u20132016."},{"key":"1720_CR76","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/alz.12285","volume":"17","author":"M Rahman","year":"2021","unstructured":"Rahman M, White EM, Mills C, Thomas KS, Jutkowitz E. Rural-urban differences in diagnostic incidence and prevalence of Alzheimer\u2019s disease and related dementias. Alzheimer\u2019s Dement. 2021;17:1213\u201330.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1720_CR77","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/j.1532-5415.2011.03543.x","volume":"59","author":"RE Amariglio","year":"2011","unstructured":"Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective memory complaints in older persons May indicate poor cognitive function. J Am Geriatr Soc. 2011;59:1612\u20137.","journal-title":"J Am Geriatr Soc"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01720-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:02:09Z","timestamp":1744704129000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01720-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research presented in the following manuscript was conducted in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments. Informed consent is obtained in accordance with protocols approved by the Institutional Review Board of the Albert Einstein College of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RL receives research support from the National Institutes of Health (NIH): 2PO1 AG003949 (Program Director), S&L Marx Foundation, and Czap Foundation, the US Food and Drug Administration (FDA). He serves as consultant, advisory board member, or has received honoraria from Abbvie (Allergan), American Academy of Neurology, Amgen, Biohaven, Eli Lilly, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pfizer, Teva. He holds stock options in Biohaven and Manistee. None of the other authors have disclosures to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}